<DOC>
	<DOCNO>NCT01675661</DOCNO>
	<brief_summary>The primary objective study evaluate impact N-acetylcysteine ( NAC ) 1200 mg versus match placebo ( PBO ) twice daily , add contingency management ( CM ) , cannabis use among treatment-seeking cannabis-dependent adult ( age 18-50 ) .</brief_summary>
	<brief_title>Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment</brief_title>
	<detailed_description>The primary objective Phase 3 study evaluate impact NAC 1200 mg versus match placebo ( PBO ) twice daily , add contingency management ( CM ) , cannabis use among treatment-seeking cannabis-dependent adult ( age 18-50 ) . After assessment inclusion study , participant randomize receive 12-week course NAC 1200 mg match placebo twice daily . All participant concurrently participate twice-weekly contingency management ( CM ) intervention . Medication management conduct weekly throughout treatment medical clinician . Urine cannabinoid test occur visit , use primary determinant cannabis use . Participants return approximately four week treatment conclusion evaluation adverse event medication discontinuation sustain treatment effect .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Age 1850 year Must able understand study provide write informed consent Must meet current DSMIV criterion cannabis dependence last 30 day Must express interest treatment cannabis dependence Must submit positive urine cannabinoid test screen Women child bear potential must agree use appropriate birth control method study participation : oral contraceptive , contraceptive patch , barrier ( diaphragm condom ) , levonorgestrel implant , medroxyprogesterone acetate , complete abstinence sexual intercourse , hormonal contraceptive vaginal ring Allergy intolerance NAcetylcysteine Women pregnant lactate Current use NAC supplement contain NAcetylcysteine ( must agree take supplement throughout study participation ) Use carbamazepine nitroglycerin within 14 day randomization Current enrollment treatment cannabis dependence Any use synthetic cannabinoids ( K2/Spice ) 30 day prior screen period screen randomization Current substance dependence , cannabis nicotine Urine drug screen positive drug abuse cannabis amphetamine randomization visit ( Only participant valid prescription amphetamine ( e.g. , ADHD ) may include ) Urine drug screen positive amphetamine randomization visit without valid prescription Maintenance treatment buprenorphine methadone Recent history asthma ( within last 3 year ) History seizure disorder , bipolar disorder , schizophrenia , significant unstable medical psychiatric illness may place participant increase risk judgment medical clinician Significant risk homicide suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>